| Literature DB >> 27883373 |
Hyun Jun Lee1, Young Eun Seo1, Seung Beom Han1,2, Dae Chul Jeong1,3, Jin Han Kang1,3.
Abstract
BACKGROUND: Although adenovirus (ADV) infection occurs steadily all year round in Korea and the identification of respiratory viral coinfections has been increasing following the introduction of multiplex real-time polymerase chain reaction tests, the clinical impact of viral coinfection in children with ADV infection has rarely been reported.Entities:
Keywords: Adenoviridae; Child; Coinfection; Prognosis
Year: 2016 PMID: 27883373 PMCID: PMC5204010 DOI: 10.3947/ic.2016.48.4.309
Source DB: PubMed Journal: Infect Chemother ISSN: 1598-8112
The frequency of respiratory viral coinfections
| Virus | Number (%) |
|---|---|
| Rhinovirusa,b,c | 15 (41.7) |
| Respiratory syncytial virus | 7 (19.4) |
| Coronavirusa | 6 (16.7) |
| Human bocavirusb | 6 (16.7) |
| Influenza B virusc | 1 (2.8) |
| Human metapneumovirus | 1 (2.8) |
| Influenza A virus | 0 (0.0) |
| Parainfluenza virus | 0 (0.0) |
| Total | 36 (100.0) |
aRhinovirus and coronavirus were concurrently identified in one child.
bRhinovirus and human bocavirus were concurrently identified in two children.
cRhinovirus and influenza B virus were concurrently identified in one child.
Comparison of demographic and clinical characteristics between ADV and coinfection groups
| Factor | ADV group (n = 73) | Coinfection group (n = 32) | ADV with rhinovirus group (n = 15) | ADV with RSV group (n = 7) | |
|---|---|---|---|---|---|
| Age group | <0.001 | ||||
| < 24 months | 20 (27.4) | 23 (71.9) | 10 (66.7)b | 6 (85.7)c | |
| ≥ 24 months | 53 (72.6) | 9 (28.1) | 5 (33.3) | 1 (14.3) | |
| Sex, male | 41 (56.2) | 19 (59.4) | 10 (66.7) | 5 (71.4) | 0.760 |
| Presence of siblings | 37 (50.7) | 8 (53.3) | 5 (71.4) | 0.818 | |
| Number of siblings, persons, median (range) | 1 (0–2) | 1 (0–2) | 1 (0–2) | 1 (0–2) | 0.647 |
| Underlying medical conditions | 5 (6.8) | 8 (25.0) | 5 (33.3)b | 3 (42.9)c | 0.020 |
| Prematurity | 5 (6.8) | 6 (18.8) | 3 (20.0) | 3 (42.9) | |
| Bronchopulmonary dysplasia | 3 (4.1) | 5 (15.6) | 2 (13.3) | 3 (42.9) | |
| Congenital hypotonia | 0 (0.0) | 1 (3.1) | 1 (6.7) | 0 (0.0) | |
| Esophageal atresia | 0 (0.0) | 1 (3.1) | 1 (6.7) | 0 (0.0) | |
| Duration of fever, days, median (range) | |||||
| Before admission | 3 (0–9) | 3 (0–10) | 3 (1–7) | 2 (0–5) | 0.561 |
| As a whole | 5 (0–10) | 5 (1–13) | 5 (2–10) | 5 (1–7) | 0.367 |
| Presenting symptoms | |||||
| Fever | 72 (98.6) | 32 (100.0) | 15 (100.0) | 7 (100.0) | 1.000 |
| Respiratory symptoms | 57 (78.1) | 30 (93.8) | 14 (93.3) | 7 (100.0) | 0.050 |
| Gastrointestinal symptoms | 17 (23.3) | 7 (21.9) | 5 (33.3) | 0 (0.0) | 0.874 |
| Ophthalmologic symptoms | 14 (19.2) | 4 (12.5) | 1 (6.7) | 0 (0.0) | 0.403 |
| Neurologic symptoms | 4 (5.5) | 3 (9.4) | 2 (13.3) | 0 (0.0) | 0.433 |
| Dermatologic symptoms | 3 (4.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.551 |
| Without localizing signs | 5 (6.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.320 |
| Clinical diagnosis | 0.011 | ||||
| Upper respiratory tract infection | 41 (56.2) | 15 (46.9) | 6 (40.0) | 3 (42.9) | |
| Acute pharyngitis | 29 (39.7) | 13 (40.6) | 5 (33.3) | 3 (42.9) | |
| Pharyngoconjunctival fever | 12 (16.4) | 2 (6.3) | 1 (6.7) | 0 (0.0) | |
| Lower respiratory tract infection | 16 (21.9) | 16 (50.0) | 9 (60.0)b | 4 (57.1) | |
| Pneumonia | 12 (16.4) | 10 (31.3) | 6 (40.0) | 1 (14.3) | |
| Acute bronchiolitis/bronchitis | 4 (5.5) | 6 (18.8) | 3 (20.0) | 3 (42.8) | |
| Acute gastroenteritis | 8 (11.0) | 1 (3.1) | 0 (0.0) | 0 (0.0) | |
| Others | 8 (11.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Duration of hospitalization, days, median (range) | 5 (3–54) | 6 (3–9) | 5 (4–7) | 6 (3–7) | 0.162 |
| Severe infection | |||||
| Oxygen therapy | 1 (1.4) | 4 (12.5) | 1 (6.7) | 2 (28.6)c | 0.029 |
| Intensive care unit admission | 1 (1.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1.000 |
| Death | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA |
a P-values for comparison between ADV and coinfection groups.
b P-values < 0.05 for comparison between ADV group and ADV with rhinovirus coinfection group.
c P-values < 0.05 for comparison between ADV group and ADV with RSV coinfection group.
ADV, adenoviurs; RSV, respiratory syncytial virus; NA, not available.
Comparison of laboratory test results between ADV and coinfection groups
| Factor | ADV group ( | Coinfection group ( | |
|---|---|---|---|
| WBC count, /mm3, median (range) | 12,550 (1,770-34,510) | 13,230 (5,410-29,260) | 0.559 |
| ANC, /mm3, median (range) | 7,967 (50-25,848) | 6,649 (581-22,150) | 0.465 |
| ALC, /mm3, median (range) | 2,910 (589-8,888) | 4,116 (1,438-10,382) | 0.005 |
| AMC, /mm3, median (range) | 1,260 (142-4,401) | 1,410 (470-2,871) | 0.452 |
| Platelet count, /mm3, median (range) | 258,000 (69,000-582,000) | 288,000 (130,000-471,000) | 0.138 |
| ESR, mm/hr, median (range)a | 45 (2-97) | 33 (2-120) | 0.244 |
| CRP, mg/dL, median (range) | 4.67 (0.02-26.94) | 2.61 (0.02-14.69) | 0.244 |
| AST over two times of upper normal limit | 1 (1.4) | 3 (9.4) | 0.083 |
| ALT over two times of upper normal limit | 1 (1.4) | 1 (3.1) | 0.519 |
aESR was tested in 100 children (70 in the adenovirus group, 30 in the coinfection group)
ADV, adenovirus; WBC, white blood cell; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; AST, aspartate transaminase; ALT, alanine transaminase.
Multivariate analysis to determine the factors significantly associated with respiratory viral coinfections
| Factor | Odds ratio | 95% confidence interval | |
|---|---|---|---|
| Age < 24 months | 8.967 | 3.075–26.151 | <0.001 |
| Underlying medical problems | 1.216 | 0.224–6.592 | 0.821 |
| Diagnosis of lower respiratory tract infection | 1.788 | 0.551–5.805 | 0.334 |